Iterum Therapeutics Plc(ITRM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ITRM Iterum Therapeutics Plc

Closed 02-23 16:00:00 EST

0.2020

-0.0100

-4.72%

盘后0.2100

+0.0080+3.96%

19:59 EST

High0.2373	Low0.1952	Vol835.28K
Open0.2202	D1 Closing0.2120	Amplitude19.86%
Mkt Cap10.66M	Tradable Cap10.58M	Total Shares52.79M
T/O171.64K	T/O Rate1.59%	Tradable Shares52.38M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ITRM","market":"US","secType":"STK","nameCN":"Iterum Therapeutics Plc","latestPrice":0.202,"timestamp":1771880400000,"preClose":0.212,"halted":0,"volume":835282,"hourTrading":{"tag":"盘后","latestPrice":0.21,"preClose":0.202,"latestTime":"19:59 EST","volume":7973,"amount":1689.742,"timestamp":1771894775477,"change":0.008,"changeRate":0.039604,"amplitude":0.083168},"delay":0,"changeRate":-0.04716981132075463,"floatShares":52375800,"shares":52787679,"eps":-0.736596,"marketStatus":"Closed","change":-0.01,"latestTime":"02-23 16:00:00 EST","open":0.2202,"high":0.2373,"low":0.1952,"amount":171638.49811458,"amplitude":0.198585,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.736596,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771923600000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1527220800000,"exchange":"NASDAQ","adjPreClose":0.212,"preHourTrading":{"tag":"盘前","latestPrice":0.2299,"preClose":0.212,"latestTime":"09:21 EST","volume":18714,"amount":4081.58571762,"timestamp":1771856493208,"change":0.0179,"changeRate":0.084434,"amplitude":0.117453},"postHourTrading":{"tag":"盘后","latestPrice":0.21,"preClose":0.202,"latestTime":"19:59 EST","volume":7973,"amount":1689.742,"timestamp":1771894775477,"change":0.008,"changeRate":0.039604,"amplitude":0.083168},"volumeRatio":0.927818},"requestUrl":"/m/hq/s/ITRM/tweets","defaultTab":"tweets","newsList":[{"id":"2612267988","title":"Iterum Therapeutics PLC  expected to post a loss of 14 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2612267988","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612267988?lang=en_us&edition=fundamental","pubTime":"2026-02-20 21:54","pubTimestamp":1771595645,"startTime":"0","endTime":"0","summary":"Iterum Therapeutics PLC  expected to post a loss of14cents a share - Earnings Preview Iterum Therapeutics PLC ITRM.OQ ITRM.O is expected to  show a rise in quarterly revenue when it reports  results o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nL8N3ZG14N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ITRM"],"gpt_icon":0},{"id":"2612422300","title":"Iterum Therapeutics plc held an extraordinary general meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2612422300","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612422300?lang=en_us&edition=fundamental","pubTime":"2026-02-19 06:06","pubTimestamp":1771452403,"startTime":"0","endTime":"0","summary":"Iterum Therapeutics plc held an extraordinary general meeting on February 18, 2026. Shareholders did not approve an increase in authorized share capital, did not approve updated board authority to allot and issue shares and related equity instruments, did not approve an opt-out of pre-emption rights for cash share issuances, and did not approve a reverse share split.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iterum Therapeutics plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL8NJJ2G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITRM","BK4007"],"gpt_icon":0},{"id":"2611150998","title":"BRIEF-Iterum Therapeutics Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2611150998","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611150998?lang=en_us&edition=fundamental","pubTime":"2026-02-13 21:45","pubTimestamp":1770990324,"startTime":"0","endTime":"0","summary":"BRIEF-Iterum Therapeutics Provides Business UpdateFeb 13 (Reuters) - Iterum Therapeutics PLC ITRM.O:ITERUM THERAPEUTICS PROVIDES BUSINESS UPDATEITERUM THERAPEUTICS PLC - FDA RECOMMENDS TYPE C MEETING ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nTUA7SM2R5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ITRM"],"gpt_icon":1},{"id":"2611524861","title":"Iterum Therapeutics Granted U.S. Patent Covering ORLYNVAH™ Bilayer Tablet, Expiring 2039","url":"https://stock-news.laohu8.com/highlight/detail?id=2611524861","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611524861?lang=en_us&edition=fundamental","pubTime":"2026-02-13 21:00","pubTimestamp":1770987645,"startTime":"0","endTime":"0","summary":"Iterum Therapeutics announced it has been granted a U.S. patent, number 12,544,337, covering a bilayer tablet comprising sulopenem etzadroxil and probenecid, methods for making the tablet, and methods for treating diseases such as uncomplicated urinary tract infection. The patent is projected to expire in December 2039, assuming all maintenance fees are paid and no term extensions are applied. This patent is eligible for listing in the FDA's Orange Book and would bring the total number of Iterum's U.S. patents listed there to five.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iterum Therapeutics plc published the original content used to generate this news brief via GlobeNewswire  on February 13, 2026, and is solely responsible for t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL7Q68Kw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","LU2095319765.USD","LU2210149790.SGD","NDAQ","IE00BKPKM429.USD","LU0314104364.USD","IE00B3QW5Z07.USD","BK4112","SG9999014005.SGD","SG9999014039.USD","LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","ITRM","SG9999014021.USD","BK4007","IE00B64PRP62.GBP","BK4588"],"gpt_icon":0},{"id":"2611152178","title":"Iterum Therapeutics Plc - FDA Recommends Type C Meeting for Iterum's Clinical Investigation","url":"https://stock-news.laohu8.com/highlight/detail?id=2611152178","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611152178?lang=en_us&edition=fundamental","pubTime":"2026-02-13 21:00","pubTimestamp":1770987602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nTUA7SM2R5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ITRM"],"gpt_icon":0},{"id":"2593452014","title":"Iterum Therapeutics plc Announces Date for Upcoming Extraordinary General Meeting of Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2593452014","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593452014?lang=en_us&edition=fundamental","pubTime":"2025-12-24 06:16","pubTimestamp":1766528189,"startTime":"0","endTime":"0","summary":"Iterum Therapeutics plc has announced that it will hold an Extraordinary General Meeting of Shareholders at its location in Dublin, Ireland, in 2026. Shareholders will be asked to vote on several proposals, including the approval of an increase in the authorized share capital of the company from $1,800,000 to $2,300,000 by the creation of an additional 50,000,000 ordinary shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iterum Therapeutics plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 23, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL490D7f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITRM","BK4007"],"gpt_icon":0},{"id":"2593749041","title":"Iterum Therapeutics Secures Major PBM Contract for ORLYNVAH Coverage","url":"https://stock-news.laohu8.com/highlight/detail?id=2593749041","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593749041?lang=en_us&edition=fundamental","pubTime":"2025-12-23 21:00","pubTimestamp":1766494833,"startTime":"0","endTime":"0","summary":"Iterum Therapeutics plc announced the expansion of market access for its antibiotic product, ORLYNVAH, through a new commercial contract with a Group Purchasing Organization working with one of the largest Pharmacy Benefit Managers  in the United States. This agreement is expected to provide coverage opportunities for more than 24 million lives starting in early 2026. In addition, Iterum Therapeutics has signed another rebate agreement with one of the top three Medicare Part D PBMs, positioning ORLYNVAH for inclusion on Medicare Advantage Prescription Drug and Medicare Prescription Drug formularies, with coverage for over 10 million lives anticipated to begin as early as the first quarter of 2026. The company expects to finalize additional agreements with other major PBMs in the near future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL2J90cy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU2210149790.SGD","SG9999014005.SGD","BK4112","SG9999014013.SGD","LU0314104364.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","ITRM","BK4588","IE00BKPKM429.USD","LU2210150020.SGD","SG9999014039.USD","BK4585","LU2095319765.USD","SG9999014021.USD","NDAQ"],"gpt_icon":0},{"id":"2592899046","title":"BRIEF-Iterum Therapeutics Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2592899046","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592899046?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:07","pubTimestamp":1765976839,"startTime":"0","endTime":"0","summary":"BRIEF-Iterum Therapeutics Provides Business UpdateDec 17 (Reuters) - Iterum Therapeutics PLC ITRM.O:ITERUM THERAPEUTICS PROVIDES BUSINESS UPDATESource text: ID:nGNX19tZ6hFurther company coverage: ITRM.O ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA2YVK5M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITRM","BK4007"],"gpt_icon":0},{"id":"2592955990","title":"Iterum Therapeutics Announces Japanese Patent Office Decision to Grant Patent Covering Sulopenem Combination, Expiring in 2041","url":"https://stock-news.laohu8.com/highlight/detail?id=2592955990","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592955990?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:01","pubTimestamp":1765976465,"startTime":"0","endTime":"0","summary":"Iterum Therapeutics Announces Japanese Patent Office Decision to Grant Patent Covering Sulopenem Combination, Expiring in 2041. Iterum Therapeutics announced that the Japanese Patent Office has issued a Decision to Grant for Japanese Patent Application No. 2022-554381, titled \"Combinations of Beta-Lactam Compounds, Probenecid, and Valproic Acid and Uses Thereof.\" The allowed claims cover a combination of sulopenem etzadroxil, probenecid, and valproic acid for treating specified diseases. Once issued, the patent is expected to expire in March 2041, subject to timely payment of maintenance fees and absent any extensions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iterum Therapeutics plc published the original content used to generate","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL5spmj3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU0314104364.USD","LU2210149790.SGD","SG9999014005.SGD","IE00B64PRP62.GBP","SG9999014021.USD","SG9999014013.SGD","BK4585","SG9999014039.USD","BK4007","LU2210150020.SGD","ITRM","NDAQ","IE00B3QW5Z07.USD","BK4588","LU2095319765.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2591684648","title":"Iterum Therapeutics Faces Nasdaq Delisting Risk Over Listing Rule Noncompliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2591684648","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591684648?lang=en_us&edition=fundamental","pubTime":"2025-12-13 06:01","pubTimestamp":1765576893,"startTime":"0","endTime":"0","summary":"Iterum Therapeutics plc is facing potential delisting from the Nasdaq Capital Market after receiving notices from the exchange regarding non-compliance with several continued listing requirements. The company failed to meet the minimum Market Value of Listed Securities  of $35 million for 30 consecutive business days, as required by Nasdaq Listing Rule 5550. Additionally, Iterum Therapeutics remains out of compliance with the minimum $1.00 bid price required under Nasdaq Listing Rule 5550. If the company does not regain compliance by the specified deadlines, its securities may be subject to delisting, though it may appeal any delisting determination. The notifications currently have no immediate effect on the company's listing status.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpre","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDLc64Hy9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITRM","BK4007"],"gpt_icon":0},{"id":"2589897621","title":"BRIEF-Iterum Therapeutics Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2589897621","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589897621?lang=en_us&edition=fundamental","pubTime":"2025-12-05 21:03","pubTimestamp":1764939838,"startTime":"0","endTime":"0","summary":"BRIEF-Iterum Therapeutics Provides Business UpdateDec 5 (Reuters) - Iterum Therapeutics PLC ITRM.O:ITERUM THERAPEUTICS PROVIDES BUSINESS UPDATEITERUM THERAPEUTICS PLC - REBATE AGREEMENT SIGNED WITH TO","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nTUA4WG5T9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITRM","BK4007"],"gpt_icon":0},{"id":"2589662897","title":"Iterum Therapeutics Plc - Rebate Agreement Signed With Top Medicare Part D Manager","url":"https://stock-news.laohu8.com/highlight/detail?id=2589662897","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589662897?lang=en_us&edition=fundamental","pubTime":"2025-12-05 21:00","pubTimestamp":1764939603,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nTUA4WG5T9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ITRM","BK4007"],"gpt_icon":0},{"id":"2584136992","title":"Director Michael W. Dunne Acquires Common Shares of Iterum Therapeutics plc","url":"https://stock-news.laohu8.com/highlight/detail?id=2584136992","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584136992?lang=en_us&edition=fundamental","pubTime":"2025-11-20 20:00","pubTimestamp":1763640046,"startTime":"0","endTime":"0","summary":"Michael W. Dunne, Director at Iterum Therapeutics plc, has reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iterum Therapeutics plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 20, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL9kDmHM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Director Michael W. Dunne Acquires Common Shares of Iterum Therapeutics plc","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITRM","BK4007"],"gpt_icon":0},{"id":"2583503898","title":"Iterum Therapeutics Q3 Adjusted EPS USD -0.16","url":"https://stock-news.laohu8.com/highlight/detail?id=2583503898","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583503898?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:05","pubTimestamp":1763121934,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nPLX7B8088:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ITRM"],"gpt_icon":0},{"id":"2583503895","title":"Iterum Therapeutics Plc: Extends Cash Runway Into Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2583503895","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583503895?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:00","pubTimestamp":1763121602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nTUA3YPH43:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ITRM"],"gpt_icon":0},{"id":"2583038815","title":"Press Release: Iterum Therapeutics Reports Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583038815","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583038815?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:00","pubTimestamp":1763121600,"startTime":"0","endTime":"0","summary":"--Commercially Launched ORLYNVAH in the United States in August 2025--. DUBLIN, Ireland and CHICAGO, Nov. 14, 2025  -- Iterum Therapeutics plc  , a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the quarter ended September 30, 2025.\"We are thrilled to have launched ORLYNVAH in the United States in August 2025 for the treatment of uncomplicated urinary tract infections ,\" said Corey Fishman, Chief Executive Officer of Iterum Therapeutics. \"The significance of this milestone cannot be overstated--particularly given the importance of bringing a new treatment option to the uUTI space where antibiotic resistance continues to erode the efficacy of existing oral therapies and there have been no new branded launches for over 25 years. Given our limited commercial infrastructure and consistent with historical antibiotic launches, we an","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1883839398.USD","IE00BLSP4452.SGD","SG9999011175.SGD","LU0321505868.SGD","LU2237443622.USD","LU2746668974.SGD","BK4006","LU0234572021.USD","LU2237443978.SGD","BK4533","BK4555","CMC","03160","LENZ","LU0122379950.USD","LU0321505439.SGD","BK4534","LU0456855351.SGD","BK4539","LU1057294990.SGD","ITRM","IE00BFXG1179.USD","SG9999003800.SGD","LU0170899867.USD","LU2237443549.SGD","LU0225284248.USD","LU1894683264.USD","LU2237443895.HKD","BK4585","LU0289739699.SGD","BK4581","LU0267386448.USD","SG9999013999.USD","LU0868494617.USD","LU1894683348.USD","TM","LU1066051498.USD","BK4604","IE000M9KFDE8.USD","IE0002270589.USD","BK4592","SG9999001176.SGD","IE00B19Z3B42.SGD","LU0882574139.USD","IE00BBT3K403.USD","LU0149725797.USD","LU1066053197.SGD","IE00B19Z3581.USD","LU2746668461.USD"],"gpt_icon":1},{"id":"2582874342","title":"Top Stocks With Earnings This Week: Plug, Oklo, Circle And More","url":"https://stock-news.laohu8.com/highlight/detail?id=2582874342","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582874342?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:38","pubTimestamp":1762781917,"startTime":"0","endTime":"0","summary":"Here&#39;s a look at this week&#39;s earnings reports that are most likely to be watched by retail investors, including Oklo, Plug and Circle.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"d36bfa730d18775aec9ad51d0643309e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/earnings/25/11/48750317/top-stocks-with-earnings-this-week-plug-oklo-circle-and-more","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LAZR","LU1688375341.USD","MVIS","CRVW","USAW.SI","MNQmain","SQQQ","IZEA","OKLO","TSYW.SI",".IXIC","CRMD","QID","CSCO","SPCE","MVST","TRNR","DIS","PSQ","PSFE","LU1823568750.SGD","RUM","ITRM","TQQQ","QLD","SERV","USJW.SI","WKHS","ZBAO","LMFA","NVIW.SI","B","CAPR","PLUG","AMAT","NQmain","NUWE"],"gpt_icon":1},{"id":"2581844508","title":"Iterum Therapeutics PLC  expected to post a loss of 11 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581844508","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581844508?lang=en_us&edition=fundamental","pubTime":"2025-11-07 23:22","pubTimestamp":1762528924,"startTime":"0","endTime":"0","summary":"Iterum Therapeutics PLC  expected to post a loss of11cents a share - Earnings Preview Iterum Therapeutics PLC ITRM.OQ ITRM.O is expected to  show no change in quarterly revenue when it reports  result","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ24T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITRM","BK4007"],"gpt_icon":0},{"id":"2572510315","title":"Maxim Group Sticks to Their Buy Rating for Iterum Therapeutics (ITRM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2572510315","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572510315?lang=en_us&edition=fundamental","pubTime":"2025-10-02 21:15","pubTimestamp":1759410926,"startTime":"0","endTime":"0","summary":"Maxim Group analyst Jason McCarthy reiterated a Buy rating on Iterum Therapeutics today and set a price target of $5.00. The company’s shares close...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/maxim-group-sticks-to-their-buy-rating-for-iterum-therapeutics-itrm-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/maxim-group-sticks-to-their-buy-rating-for-iterum-therapeutics-itrm-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ITRM"],"gpt_icon":0},{"id":"2568268010","title":"Iterum Therapeutics sees cash runway into 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2568268010","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568268010?lang=en_us&edition=fundamental","pubTime":"2025-09-19 20:10","pubTimestamp":1758283843,"startTime":"0","endTime":"0","summary":"Iterum Therapeutics (ITRM) provided a general business update. ORLYNVAH Launch Update: In partnership with EVERSANA Life Science Services, ORLYNVAH...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/iterum-therapeutics-sees-cash-runway-into-2026-thefly-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/iterum-therapeutics-sees-cash-runway-into-2026-thefly-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","ITRM","BK4539","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.iterumtx.com","stockEarnings":[{"period":"1week","weight":-0.2285},{"period":"1month","weight":-0.3312},{"period":"3month","weight":-0.4511},{"period":"6month","weight":-0.7151},{"period":"1year","weight":-0.8577},{"period":"ytd","weight":-0.3672}],"compareEarnings":[{"period":"1week","weight":0.0113},{"period":"1month","weight":0.0059},{"period":"3month","weight":0.0461},{"period":"6month","weight":0.0684},{"period":"1year","weight":0.1295},{"period":"ytd","weight":0.011}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":0.037259},{"month":2,"riseRate":0.375,"avgChangeRate":-0.065819},{"month":3,"riseRate":0.428571,"avgChangeRate":0.03951},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.003506},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.011866},{"month":6,"riseRate":0.25,"avgChangeRate":-0.066662},{"month":7,"riseRate":0.25,"avgChangeRate":-0.137259},{"month":8,"riseRate":0.125,"avgChangeRate":-0.101164},{"month":9,"riseRate":0.125,"avgChangeRate":-0.10016},{"month":10,"riseRate":0.25,"avgChangeRate":-0.145222},{"month":11,"riseRate":0.5,"avgChangeRate":0.284433},{"month":12,"riseRate":0.375,"avgChangeRate":0.016309}],"exchange":"NASDAQ","name":"Iterum Therapeutics Plc","nameEN":"Iterum Therapeutics Plc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Iterum Therapeutics Plc(ITRM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Iterum Therapeutics Plc(ITRM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Iterum Therapeutics Plc,ITRM,Iterum Therapeutics Plc股票,Iterum Therapeutics Plc股票老虎,Iterum Therapeutics Plc股票老虎国际,Iterum Therapeutics Plc行情,Iterum Therapeutics Plc股票行情,Iterum Therapeutics Plc股价,Iterum Therapeutics Plc股市,Iterum Therapeutics Plc股票价格,Iterum Therapeutics Plc股票交易,Iterum Therapeutics Plc股票购买,Iterum Therapeutics Plc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Iterum Therapeutics Plc(ITRM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Iterum Therapeutics Plc(ITRM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction